查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
出血性疾病治疗药的全球市场 (～2027年):各药物类型、疾病类型、流通管道、终端用户、地区的竞争、机会、预测
市场调查报告书
商品编码
1121071

出血性疾病治疗药的全球市场 (～2027年):各药物类型、疾病类型、流通管道、终端用户、地区的竞争、机会、预测

Global Bleeding Disorders Treatment Market By Drug Type, By Disease Type, By Distribution Channel, By End User By Region, Competition, Forecast & Opportunities, 2027
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球出血性疾病治疗药的市场，从预测期间的2023年到2027年预计记录稳定的年复合成长率。

患者人口增加，公民营的经营者的医疗支出增加，中游家庭的可支配所得增加等要素牵引该市场。还有R&D活动的进展，及製药公司着重基因改造产品，今后5年预计创造市场有利的成长机会。

本报告提供全球出血性疾病治疗药的市场调查，市场概要，市场规模的变化、预测，各种区分、各地区/主要国家的明细，市场的各种影响因素的分析，竞争环境，市场占有率，主要企业简介等彙整资讯。

目录

第1章 产品概要

第2章 调查手法

第3章 摘要整理

第4章 COVID-19:对全球出血性疾病治疗药市场的影响

第5章 VOC (客户的迴响)

第6章 全球出血性疾病治疗药市场预测

  • 市场规模、预测
  • 市场占有率、预测
    • 各药物类型(血浆来源凝固凝血因子浓缩剂、重组凝固凝血因子浓缩剂、去氨加压素、抗线溶药、纤维蛋白胶、其他)
    • 各疾病类型(A型血友病、B型血友病、类血友病病、其他)
    • 各流通管道(医院药局、零售药局、线上)
    • 各终端用户(诊所、医院、研究机关、其他)
    • 各企业
    • 各地区(北美、欧洲、亚太地区、南美、中东&非洲)
  • 产品市场地图

第7章 北美的出血性疾病治疗药市场预测

  • 市场规模、预测
  • 市场占有率、预测
    • 各药物类型
    • 各疾病类型
    • 各流通管道
    • 各终端用户
    • 各国
  • 各国分析

第8章 欧洲的出血性疾病治疗药市场预测

  • 市场规模、预测
  • 市场占有率、预测
    • 各药物类型
    • 各疾病类型
    • 各流通管道
    • 各终端用户
    • 各国
  • 各国分析

第9章 亚太地区的出血性疾病治疗药市场预测

  • 市场规模、预测
  • 市场占有率、预测
    • 各药物类型
    • 各疾病类型
    • 各流通管道
    • 各终端用户
    • 各国
  • 各国分析

第10章 中东及非洲的出血性疾病治疗药市场预测

  • 市场规模、预测
  • 市场占有率、预测
    • 各药物类型
    • 各疾病类型
    • 各流通管道
    • 各终端用户
    • 各国
  • 各国分析

第11章 南美的出血性疾病治疗药市场预测

  • 市场规模、预测
  • 市场占有率、预测
    • 各药物类型
    • 各疾病类型
    • 各流通管道
    • 各终端用户
    • 各国
  • 各国分析

第12章 市场动态

  • 促进因素
  • 课题

第13章 市场趋势、市场展开

第14章 竞争情形

  • 竞争预测
  • 全球企业简介
    • Bayer AG
    • Pfizer Inc.
    • Grifols S.A.
    • Octapharma AG
    • Sun Pharmaceuticals Industries Ltd.
    • Ferring Pharmaceuticals SA
    • Amgen Inc.
    • Sanofi SA
    • Baxter International Inc.
    • F. Hoffmann-La Roche Ltd.
    • Takeda Pharmaceuticals Ltd.
    • Novo Nordisk A/S
    • Novartis AG
    • Eli Lilly and Company Ltd.
    • Gilead Sciences Inc.

第15章 策略性建议

第16章 关于本公司&免责声明

简介目录
Product Code: 7317

The global bleeding disorders treatment market is projected to witness a steady CAGR during the forecast period, 2023-2027. Factors such as the rise in the patient population base, increased healthcare expenditure by the public and private players, and growing disposable income for middle-class families drive the global bleeding disorders treatment market. The ongoing research and development activities and the increased focus of pharmaceutical companies on recombinant products are expected to create lucrative growth opportunities for the global bleeding disorders treatment market in the next five years. However, limited reimbursement and the high cost of availing of bleeding disorder treatment facilities may hinder the market growth in the forecast period.

The global bleeding disorders treatment market is segmented into drug type, disease type, distribution channel, end user, regional distribution, and competitive landscape. Based on drug type, the market is fragmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is expected to capture the highest market share during the forecast period, 2023-2027. Their high efficiency in preventing bleeding than plasma-derived coagulation factor concentrates is expected to drive the market demand in the next five years.

North America is expected to dominate the global bleeding disorders treatment market in the forecast period. The compatibility of the population of all age groups in the United States for prophylaxis treatment is driving the market demand in the region.

The major players operating in the global bleeding disorders treatment market are: Bayer AG, Pfizer Inc., Grifols S.A., Octapharma AG, Sun Pharmaceuticals Industries Ltd., Ferring Pharmaceuticals SA, Amgen Inc., Sanofi SA, Baxter International Inc., F. Hoffmann-La Roche Ltd., Takeda Pharmaceuticals Ltd., Novo Nordisk A/S, Novartis AG, Eli Lilly and Company Ltd., Gilead Sciences Inc., among others. The companies are focusing on extensive research and development activities to stay competitive in the market.

Years considered for this report:

  • Historical Years: 2017 - 2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023 - 2027

Objective of the Study:

  • To analyze and forecast the market size of global bleeding disorders treatment market from 2017 to 2021.
  • To estimate and forecast the market size of global bleeding disorders treatment market from 2022 to 2027 and growth rate until 2027.
  • To classify and forecast global bleeding disorders treatment market based on drug type, disease type, distribution channel, end user, and regional distribution.
  • To identify dominant region or segment in the global bleeding disorders treatment market.
  • To identify drivers and challenges for global bleeding disorders treatment market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Global bleeding disorders treatment market.
  • To identify and analyze the profile of leading players operating in Global bleeding disorders treatment market.
  • To identify key sustainable strategies adopted by market players in Global bleeding disorders treatment market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of Global bleeding disorders treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Bleeding disorders treatment vendors, end users, service providers and other stakeholders
  • Distributers and suppliers of bleeding disorders treatment's products and services and other stakeholders
  • Organizations, forums, and alliances related to bleeding disorders treatment
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Global bleeding disorders treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Drug Type:

  • Plasma-derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants
  • Others

Market, By Disease Type:

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

Market, By End User:

  • Clinics
  • Hospitals
  • Research Institutes
  • Others

Market, By Region:

  • North America
  • APAC
  • Europe
  • MEA
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global bleeding disorders treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Bleeding Disorders Treatment Market

4. Executive Summary

5. Voice of Customer

6. Global Bleeding Disorders Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others)
    • 6.2.2. By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others)
    • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)
    • 6.2.4. By End User (Clinics, Hospitals, Research Institutes, Others)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)
  • 6.3. Product Market Map

7. North America Bleeding Disorders Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Disease Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By End User
    • 7.2.5. By Country (United States; Canada; Mexico)
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Bleeding Disorders Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Distribution Channel
        • 7.3.1.2.4. By End User
    • 7.3.2. Canada Bleeding Disorders Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Distribution Channel
        • 7.3.2.2.4. By End User
    • 7.3.3. Mexico Bleeding Disorders Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Distribution Channel
        • 7.3.3.2.4. By End User

8. Europe Bleeding Disorders Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Disease Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By End User
    • 8.2.5. By Country (France; Germany; UK; Italy; Spain)
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Bleeding Disorders Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Distribution Channel
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Bleeding Disorders Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Distribution Channel
        • 8.3.2.2.4. By End User
    • 8.3.3. United Kingdom Bleeding Disorders Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Distribution Channel
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Bleeding Disorders Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Distribution Channel
        • 8.3.4.2.4. By End User
    • 8.3.5. Spain Bleeding Disorders Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Distribution Channel
        • 8.3.5.2.4. By End User

9. Asia-Pacific Bleeding Disorders Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Disease Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By End User
    • 9.2.5. By Country (China; India; Japan; South Korea; Australia)
  • 8.3 Asia-Pacific: Country Analysis
    • 8.3.1 China Bleeding Disorders Treatment Market Outlook
      • 8.3.1.1 Market Size & Forecast
        • 8.3.1.1.1 By Value
      • 8.3.1.2 Market Share & Forecast
        • 8.3.1.2.1 By Drug Type
        • 8.3.1.2.2 By Disease Type
        • 8.3.1.2.3 By Distribution Channel
        • 8.3.1.2.4 By End User
    • 8.3.2 India Bleeding Disorders Treatment Market Outlook
      • 8.3.2.1 Market Size & Forecast
        • 8.3.2.1.1 By Value
      • 8.3.2.2 Market Share & Forecast
        • 8.3.2.2.1 By Drug Type
        • 8.3.2.2.2 By Disease Type
        • 8.3.2.2.3 By Distribution Channel
        • 8.3.2.2.4 By End User
    • 8.3.3 Japan Bleeding Disorders Treatment Market Outlook
      • 8.3.3.1 Market Size & Forecast
        • 8.3.3.1.1 By Value
      • 8.3.3.2 Market Share & Forecast
        • 8.3.3.2.1 By Drug Type
        • 8.3.3.2.2 By Disease Type
        • 8.3.3.2.3 By Distribution Channel
        • 8.3.3.2.4 By End User
    • 8.3.4 South Korea Bleeding Disorders Treatment Market Outlook
      • 8.3.4.1 Market Size & Forecast
        • 8.3.4.1.1 By Value
      • 8.3.4.2 Market Share & Forecast
        • 8.3.4.2.1 By Drug Type
        • 8.3.4.2.2 By Disease Type
        • 8.3.4.2.3 By Distribution Channel
        • 8.3.4.2.4 By End User
    • 8.3.5 Australia Bleeding Disorders Treatment Market Outlook
      • 8.3.5.1 Market Size & Forecast
        • 8.3.5.1.1 By Value
      • 8.3.5.2 Market Share & Forecast
        • 8.3.5.2.1 By Drug Type
        • 8.3.5.2.2 By Disease Type
        • 8.3.5.2.3 By Distribution Channel
        • 8.3.5.2.4 By End User

10. Middle East and Africa Bleeding Disorders Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Disease Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By End User
    • 10.2.5. By Country (UAE; Saudi Arabia; South Africa)
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bleeding Disorders Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Distribution Channel
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Bleeding Disorders Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Distribution Channel
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Bleeding Disorders Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Distribution Channel
        • 10.3.3.2.4. By End User

11. South America Bleeding Disorders Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type
    • 11.2.2. By Disease Type
    • 11.2.3. By Distribution Channel
    • 11.2.4. By End User
    • 11.2.5. By Country (Brazil; Argentina; Colombia)
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Bleeding Disorders Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Type
        • 11.3.1.2.2. By Disease Type
        • 11.3.1.2.3. By Distribution Channel
        • 11.3.1.2.4. By End User
    • 11.3.2. Argentina Bleeding Disorders Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Type
        • 11.3.2.2.2. By Disease Type
        • 11.3.2.2.3. By Distribution Channel
        • 11.3.2.2.4. By End User
    • 11.3.3. Colombia Bleeding Disorders Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Type
        • 11.3.3.2.2. By Disease Type
        • 11.3.3.2.3. By Distribution Channel
        • 11.3.3.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Global Players Profiled (Leading Companies)
    • 14.2.1. Bayer AG
    • 14.2.2. Pfizer Inc.
    • 14.2.3. Grifols S.A.
    • 14.2.4. Octapharma AG
    • 14.2.5. Sun Pharmaceuticals Industries Ltd.
    • 14.2.6. Ferring Pharmaceuticals SA
    • 14.2.7. Amgen Inc.
    • 14.2.8. Sanofi SA
    • 14.2.9. Baxter International Inc.
    • 14.2.10. F. Hoffmann-La Roche Ltd.
    • 14.2.11. Takeda Pharmaceuticals Ltd.
    • 14.2.12. Novo Nordisk A/S
    • 14.2.13. Novartis AG
    • 14.2.14. Eli Lilly and Company Ltd.
    • 14.2.15. Gilead Sciences Inc.

15. Strategic Recommendations

16. About Us & Disclaimer